A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer

Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the therapy...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncol Res
Huvudupphovsmän: Fujiwara, Atsushi, Yoshida, Masamichi, Fujimoto, Hajime, Nakahara, Hiroki, Ito, Kentaro, Nishihama, Kota, Yasuma, Taro, Hataji, Osamu, Taguchi, Osamu, D’Alessandro-Gabazza, Corina N., Gabazza, Esteban C., Kobayashi, Tetsu
Materialtyp: Artigo
Språk:Inglês
Publicerad: Cognizant Communication Corporation 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7844677/
https://ncbi.nlm.nih.gov/pubmed/29321093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504018X15151523767752
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk